Neurobiology of Aging
Volume 29, Issue 7 , Pages 1040-1051 , July 2008

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

  • Pershia Samadi

      Affiliations

    • Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada
    • Faculty of Pharmacy, Laval University, Quebec, Canada
    • ,
  • Laurent Grégoire

      Affiliations

    • Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada
    • ,
  • Marc Morissette

      Affiliations

    • Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada
    • ,
  • Fréderic Calon

      Affiliations

    • Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada
    • Faculty of Pharmacy, Laval University, Quebec, Canada
    • ,
  • Abdallah Hadj Tahar

      Affiliations

    • Neuroscience Research Centre, Laval University Medical Centre, Quebec, Canada
    • ,
  • Mehdi Dridi

      Affiliations

    • Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada
    • Faculty of Pharmacy, Laval University, Quebec, Canada
    • ,
  • Nancy Belanger

      Affiliations

    • Neuroscience Research Centre, Laval University Medical Centre, Quebec, Canada
    • ,
  • Leonard T. Meltzer

      Affiliations

    • Pfizer Global Research and Development, Ann Arbor Laboratories, Michigan, USA
    • ,
  • Paul J. Bédard

      Affiliations

    • Neuroscience Research Centre, Laval University Medical Centre, Quebec, Canada
    • Faculty of Medicine, Laval University, Quebec, Canada
    • ,
  • Thérèse Di Paolo

      Affiliations

    • Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada
    • Faculty of Pharmacy, Laval University, Quebec, Canada
    • Corresponding Author InformationCorresponding author at: Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, CHUL, 2705 Laurier Blvd, Quebec, Canada G1V 4G2. Tel.: +1 418 654 2296; fax: +1 418 654 2761.

Received 20 September 2006 ,Revised 17 January 2007 ,Accepted 5 February 2007.

References 

  1. Alagarsamy S, Saugstad J, Warren L, Mansuy IM, Gereau RW, Conn PJ. NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology. 2005;49(Suppl. 1):135–145
  2. Andine P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E, et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J. Pharmacol. Exp. Ther. 1999;290:1393–1408
  3. Bamford NS, Zhang H, Schmitz Y, Wu NP, Cepeda C, Levine MS, et al. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron. 2004;42:653–663
  4. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, et al. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Neurosci. 2004;24:828–835
  5. Belanger N, Grégoire L, Hadj TA, Bédard PJ. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 2003;18:1436–1441
  6. Blanchet PJ, Calon F, Martel JC, Bédard PJ, Di Paolo T, Walters RR, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 1995;272:854–859
  7. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 1999;290:1034–1040
  8. Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 1997;21:447–453
  9. Breysse N, Amalric M, Salin P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 2003;23:8302–8309
  10. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 2002;22:5669–5678
  11. Calabresi P, Centonze D, Bernardi G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 2000;23:S57–S63
  12. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J. Neuropathol. Exp. Neurol. 2002;61:186–196
  13. Calon F, Hadj Tahar A, Blanchet PJ, Morissette M, Grondin R, Goulet M, et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 2000;23:S92–S100
  14. Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002;26:127–138
  15. Calon F, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 2003;14:404–416
  16. Cepeda C, Colwell CS, Itri JN, Chandler SH, Levine MS. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J. Neurophysiol. 1998;79:82–94
  17. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. 2000;47:S122–S129
  18. Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 2006;69:318–326
  19. de Novellis V, Marabese I, Palazzo E, Rossi F, Berrino L, Rodella L, et al. Group I metabotropic glutamate receptors modulate glutamate and gamma-aminobutyric acid release in the periaqueductal grey of rats. Eur. J. Pharmacol. 2003;462:73–81
  20. Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006;326:483–504
  21. Francois C, Grabli D, McCairn K, Jan C, Karachi C, Hirsch EC, et al. Behavioural disorders induced by external globus pallidus dysfunction in primates. II. Anatomical study. Brain. 2004;127:2055–2070
  22. Gerfen CR. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease. Neuroscientist. 2003;9:455–462
  23. Goulet M, Morissette M, Grondin R, Falardeau P, Bédard PJ, Rostene W, et al. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Synapse. 1999;32:153–164
  24. Grabli D, McCairn K, Hirsch EC, Agid Y, Feger J, Francois C, et al. Behavioural disorders induced by external globus pallidus dysfunction in primates. I. Behavioural study. Brain. 2004;127:2039–2054
  25. Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur. J. Neurosci. 2005;22:283–287
  26. Hadj Tahar A, Grégoire L, Darre A, Belanger N, Meltzer L, Bédard PJ. Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. 2004;15:171–176
  27. Heimer G, Rivlin-Etzion M, Bar-Gad I, Goldberg JA, Haber SN, Bergman H. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of parkinsonism. J. Neurosci. 2006;26:8101–8114
  28. Hubert GW, Paquet M, Smith Y. Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey Substantia nigra. J. Neurosci. 2001;21:1838–1847
  29. Kita H, Tachibana Y, Nambu A, Chiken S. Balance of monosynaptic excitatory and disynaptic inhibitory responses of the globus pallidus induced after stimulation of the subthalamic nucleus in the monkey. J. Neurosci. 2005;25:8611–8619
  30. Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, Dekundy A, et al. Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. 2004;17:219–236
  31. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature. 1999;399:A7–A14
  32. Loftis JM, Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 2003;97:55–85
  33. Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 1997;17:5196–5205
  34. Marino MJ, Awad H, Poisik O, Wittmann M, Conn PJ. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Amino Acids. 2002;23:185–191
  35. Marino MJ, Conn JP. Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. Curr. Drug Targets. CNS. Neurol. Disord. 2002;1:239–250
  36. Mercuri NB, Bernardi G. The ‘magic’ of l-dopa: why is it the gold standard Parkinson's disease therapy?. Trends Pharmacol. Sci. 2005;26:341–344
  37. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov. Disord. 2000;15:3–8
  38. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, et al. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov. Disord. 2006;21:9–17
  39. Nambu A, Tokuno H, Hamada I, Kita H, Imanishi M, Akazawa T, et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J. Neurophysiol. 2000;84:289–300
  40. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 2000;20:7782–7789
  41. Nikam SS, Meltzer LT. NR2B selective NMDA receptor antagonists. Curr. Pharm. Des. 2002;8:845–855
  42. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 2000;23:S109–S115
  43. Ossowska K, Konieczny J, Wolfarth S, Pilc A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology. 2005;49:447–455
  44. Oueslati A, Breysse N, Amalric M, Kerkerian-Le Goff L, Salin P. Dysfunction of the cortico-basal ganglia-cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism. Eur. J. Neurosci. 2005;22:2765–2774
  45. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 1996;39:574–578
  46. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev. 1995;20:91–127
  47. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology. 1999;38:735–767
  48. Patel S, Krause SM, Hamill T, Chaudhary A, Burns DH, Gibson RA. In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand. Life Sci. 2003;73:371–379
  49. Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F. Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J. Neurosci. 2004;24:1149–1158
  50. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons. Neuroscience. 2001;106:579–587
  51. Popoli P, Pintor A, Tebano MT, Frank C, Pepponi R, Nazzicone V, et al. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. J. Neurochem. 2004;89:1479–1489
  52. Rodrigues SM, Bauer EP, Farb CR, Schafe GE, LeDoux JE. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J. Neurosci. 2002;22:5219–5229
  53. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther. 2000;88:427–435
  54. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006;29:647–654
  55. Sealfon SC, Olanow CW. Dopamine receptors: from structure to behavior. Trends Neurosci. 2000;23:S34–S40
  56. Shohamy D, Myers CE, Grossman S, Sage J, Gluck MA. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease. Behav. Brain Res. 2005;156:191–199
  57. Sonsalla PK, Albers DS, Zeevalk GD. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids. 1998;14:69–74
  58. Szabo J, Cowan WM. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. Comp. Neurol. 1984;222:265–300
  59. Voulalas PJ, Holtzclaw L, Wolstenholme J, Russell JT, Hyman SE. Metabotropic glutamate receptors and dopamine receptors cooperate to enhance extracellular signal-regulated kinase phosphorylation in striatal neurons. J. Neurosci. 2005;25:3763–3773

PII: S0197-4580(07)00046-2

doi: 10.1016/j.neurobiolaging.2007.02.005

Neurobiology of Aging
Volume 29, Issue 7 , Pages 1040-1051 , July 2008

Article Tools

* Image Usage & Resolution